STOCK COMPARISON
Vitrolife AB vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Vitrolife AB (VITR) and Abbott Laboratories (ABT) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees Vitrolife AB as the less overvalued of the two: Vitrolife AB trades at SEK 90.00 versus a fair value of SEK 70.91 (-21%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Vitrolife AB
VITR.ST · SEK · Health Care
-21%
upside to fair value
overvalued
PriceSEK 90.00
Fair ValueSEK 70.91
Quality48/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Vitrolife ABAbbott Laboratories
Valuation
—P/E (TTM)27.7×
0.37×P/S (TTM)3.89×
0.16×P/B3.36×
2.1×EV/EBITDA15.1×
2.02×PEG1.47×
1.2%Dividend yield—
SEK 1.10Dividend per share—
Profitability
-147%Net margin14%
18%Operating margin13%
-47%Return on equity12%
3%Return on assets6%
Growth
-4%Revenue growth (YoY)8%
2.1%Avg. growth/yr (3Y)0.5%
22.5%Avg. growth/yr (5Y)5.1%
Balance & size
0.19×Debt / equity0.19×
$1BMarket cap$175B
mixedGrowth qualityhealthy
Vitrolife AB leads: 7 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Vitrolife ABof which business quality 49 · market factors 17
Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
9
50
Quality GrowthAre margins and returns improving?
20
47
CashflowEarnings quality: real cash, not paper profit
52
71
Fin. StrengthBalance sheet, leverage, solvency risk
60
80
InvestmentDisciplined investing over empire-building
89
65
Low VolatilityCalm price path (market factor)
22
83
MomentumPrice trend over the last 3–12 months (market factor)
22
40
52W MomentumDistance to the 52-week high (market factor)
5
33
Net IssuanceBuybacks instead of dilution
82
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Vitrolife AB
DCF ModelsSEK 77.32
Earnings-BasedSEK 35.09
MultiplesSEK 72.29
Asset-BasedSEK 39.05
Growth DCFSEK 74.97
Economic ProfitSEK 35.09
10 of 13 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Vitrolife AB
Bear SEK 34.07Fair Value SEK 70.91Bull SEK 90.23
SEK 90.00 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Vitrolife AB · Health Care
Quality score48 · below median
Fair value upside-21% · above median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees Vitrolife AB as the less overvalued of the two: Vitrolife AB trades at SEK 90.00 versus a fair value of SEK 70.91 (-21%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
